enzalutamide in the non-metastatic setting for crpc
Published 5 years ago • 87 plays • Length 0:42Download video MP4
Download video MP3
Similar videos
-
5:16
enzamet: enzalutamide for metastatic prostate cancer
-
3:06
enzalutamide in the context of nonmetastatic crpc
-
2:50
prosper: enzalutamide vs. placebo for nmcrpc
-
2:24
delaying disease progression in early, non-metastatic crpc treatment
-
2:13
head-to-head: tolerability of enzalutamide vs. abiraterone acetate for metastatic crpc
-
3:19
live long and prosper: enzalutamide for nmcrpc
-
4:36
nonmetastatic crpc: considerations for apalutamide
-
2:55
audio described: clinical trial tests nivolumab for patients with rare brain and spine cancers
-
1:55
awaiting key results for enzalutamide and apalutamide in nmcrpc
-
4:12
ocuu-crpc trial: enzalutamide vs. flutamide for crpc after bicalutamide
-
2:38
safety outcomes of darolutamide vs apalutamide and enzalutamide in nmcrpc
-
21:25
an update on the prosper trial: focusing on nonmetastatic crpc
-
0:51
dr. gomella on the fda approval of enzalutamide in nonmetastatic crpc
-
5:55
the future of treatment for nonmetastatic crpc
-
4:53
apalutamide: a next-gen agent for nonmetastatic crpc
-
0:44
dr. wise on the fda approval of apalutamide in non-metastatic crpc
-
1:10
preside: investigating continued treatment with enzalutamide in pc following disease progression
-
4:35
support for continuing enzalutamide after mcrpc progression | axel merseburger
-
6:51
understanding nonmetastatic crpc: an overview